Impax and Leiner
This article was originally published in The Tan Sheet
Executive Summary
Hayward, Calif. -based drug delivery firm has signed a series of agreements with Leiner for supply and distribution of Claritin equivalents slated for late-summer launch, Impax announces July 12. Products include store brand versions of Reditabs and D-24 (1"The Tan Sheet" June 21, 2004, p. 5). The deal "enables IMPAX to further capitalize on our loratadine product franchise," according to CEO Barry Edwards...
You may also be interested in...
D-24 equivalent
Ranbaxy ANDA for loratadine 10 mg/pseudoephedrine sulfate 240 mg approved Sept. 21 for over-the-counter sale. Firm joins Impax Labs in having ANDA clearance for equivalents to Schering-Plough's Claritin D-24 (1"The Tan Sheet" July 19, 2004, In Brief)...
Claritin-D Braces For Winter With Common Cold New Use Claim
Schering-Plough could leverage its new common cold usage claim for Claritin-D 12- and 24-Hour tablets as the company shifts its focus for the brand from the spring allergy season to the fall cough/cold season
Leiner Looks To Rule Claritin Equivalent Market With Summer Launches
Leiner Health Products will seek to control the store brand loratadine market with late summer launches of equivalents to Schering-Plough's Claritin RediTabs and D-24